Inhibrx Stock Quote Today

INBX -  USA Stock  

USD 25.87  2.19  7.80%

Market Performance
0 of 100
Odds Of Distress
Less than 33
Inhibrx is trading at 25.87 as of the 24th of January 2022; that is -7.8 percent decrease since the beginning of the trading day. The stock's open price was 28.06. Inhibrx has about a 33 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Inhibrx are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of February 2020 and ending today, the 24th of January 2022. Click here to learn more.
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California. Inhibrx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 37.95 M outstanding shares of which 685.9 K shares are currently shorted by private and institutional investors with about 3.55 trading days to cover. More on Inhibrx

Inhibrx Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Inhibrx's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Inhibrx or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Inhibrx generated a negative expected return over the last 90 days
Inhibrx has high historical volatility and very poor performance
The company reported the previous year's revenue of 7.15 M. Net Loss for the year was (78.23 M) with loss before overhead, payroll, taxes, and interest of (60.61 M).
Inhibrx currently holds about 112.7 M in cash with (73.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.97.
Inhibrx has a poor financial position based on the latest SEC disclosures
Roughly 40.0% of the company shares are held by company insiders
Inhibrx Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Inhibrx SEC Filings
Inhibrx SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameInhibrx
Average Analyst Recommendation
Analysts covering Inhibrx report their recommendations after researching Inhibrx's financial statements, talking to executives and customers, or listening in on Inhibrx's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Inhibrx. The Inhibrx consensus assessment is calculated by taking the average forecast from all of the analysts covering Inhibrx.
Strong Buy3 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Inhibrx based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Inhibrx financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 4 - PoorDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares27.2 M29.1 M
Notably Down
Slightly volatile
Weighted Average Shares Diluted27.2 M29.1 M
Notably Down
Slightly volatile
Total Assets178.4 M165.3 M
Significantly Up
Slightly volatile
Total Liabilities70.1 M78.5 M
Fairly Down
Slightly volatile
Current Assets164 M152 M
Significantly Up
Slightly volatile
Current Liabilities32.2 M36.1 M
Fairly Down
Slightly volatile
Total Debt39.8 M43.1 M
Significantly Down
Slightly volatile
Gross Margin0.890.9
Fairly Down
Slightly volatile
Asset Turnover0.140.14
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Inhibrx's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong BuyUndervalued
Financial Strength
Inhibrx's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Inhibrx's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Inhibrx's financial leverage. It provides some insight into what part of Inhibrx's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Inhibrx's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Inhibrx deploys its capital and how much of that capital is borrowed.
Inhibrx cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 77.17 M in liabilities with Debt to Equity (D/E) ratio of 2.74, implying the company greatly relies on financing operations through barrowing. Inhibrx has a current ratio of 4.64, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

(46.58 Million)Share
Inhibrx (INBX) is traded on NASDAQ Exchange in USA. It is located in 11025 North Torrey Pines Road and employs 84 people. Inhibrx is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 1.06 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Inhibrx's market, we take the total number of its shares issued and multiply it by Inhibrx's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Inhibrx conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 37.95 M outstanding shares of which 685.9 K shares are currently shorted by private and institutional investors with about 3.55 trading days to cover. Inhibrx currently holds about 112.7 M in cash with (73.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.97.
Check Inhibrx Probability Of Bankruptcy
Inhibrx has a total of thirty-seven million nine hundred fifty thousand outstanding shares. Over half of Inhibrx outstanding shares are owned by outside corporations. These outside corporations are typically referred to corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Inhibrx. Please watch out for any change in the institutional holdings of Inhibrx as this could mean something significant has changed or about to change at the company. Please note that no matter how much assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Inhibrx Ownership Details

Inhibrx Stock Price Odds Analysis

What are Inhibrx's target price odds to finish over the current price? Based on a normal probability distribution, the odds of Inhibrx jumping above the current price in 90 days from now is close to 99%. The Inhibrx probability density function shows the probability of Inhibrx stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.475. This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Inhibrx will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Inhibrx is significantly underperforming DOW.
 Odds Down 25.87HorizonTargetOdds Up 25.87 
0.11%90 days
Based on a normal probability distribution, the odds of Inhibrx to move above the current price in 90 days from now is close to 99 (This Inhibrx probability density function shows the probability of Inhibrx Stock to fall within a particular range of prices over 90 days) .

Inhibrx Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Inhibrx that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Inhibrx's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Inhibrx's value.
InstituionSecurity TypeTotal SharesValue
Russell Investments Group LtdCommon Shares258.6 K11.3 M
Tci Wealth Advisors IncCommon Shares105K
View Inhibrx Diagnostics

Inhibrx Historical Income Statement

Inhibrx Income Statement is one of the three primary financial statements used for reporting Inhibrx's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Inhibrx revenue and expense. Inhibrx Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Income Tax Expense is likely to rise to 2,771 in 2022, whereas Consolidated Income is likely to drop (73.9 M) in 2022. View More Fundamentals

Inhibrx Stock Against Markets

Picking the right benchmark for Inhibrx stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Inhibrx stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Inhibrx is critical whether you are bullish or bearish towards Inhibrx at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Inhibrx without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Price Ceiling Movement Now


Price Ceiling Movement

Calculate and plot Price Ceiling Movement for different equity instruments
All  Next Launch Module
Please see Risk vs Return Analysis. Note that the Inhibrx information on this page should be used as a complementary analysis to other Inhibrx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Shere Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Inhibrx Stock analysis

When running Inhibrx price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Is Inhibrx's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inhibrx. If investors know Inhibrx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inhibrx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Inhibrx is measured differently than its book value, which is the value of Inhibrx that is recorded on the company's balance sheet. Investors also form their own opinion of Inhibrx's value that differs from its market value or its book value, called intrinsic value, which is Inhibrx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inhibrx's market value can be influenced by many factors that don't directly affect Inhibrx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inhibrx's value and its price as these two are different measures arrived at by different means. Investors typically determine Inhibrx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inhibrx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.